Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib and RAD001 in Advanced Clear Cell Renal Cell Carcinoma
NCT00392821Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Dec 2006
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in clear cell renal cell carcinoma (ccRCC), sponsored by SCRI Development Innovations. Primary endpoint: Overall Response Rate at 18 months. Started Dec 2006; status: completed.
02
Drugs
everolimus
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT00392821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00392821.